The sentiment in the pharmaceutical sector is heating up. On August 24th, Magic Pharmaceuticals and Yibai Pharmaceuticals hit the daily limit up. According to data statistics, as of 10:49 on August 24th, Magic Pharmaceuticals rose 10%, with a daily limit up of 9.9 yuan. The trading volume was 931100 lots, with a turnover of 893 million yuan and a total market value of 5.287 billion yuan. The company recorded 6 daily limit ups in 8 trading days. Yibai Pharmaceutical rose 9.95%, reaching the daily limit up to 4.09 yuan, with a trading volume of 476300 lots and a turnover of 192 million yuan, and a total market value of 3.208 billion yuan.
According to the data, the main business of Magic Pharmaceuticals covers the research, development, production, and sales of various types of drugs such as anti-tumor, cardiovascular and cerebrovascular, cold and cough medicines, and belongs to the core track of chemical pharmaceuticals. For the sustained strength of Magic Pharmaceuticals, analysis points out that the core comes from the resonance of multiple speculative logics. If the company's products have a scarcity attribute, it is reported that the core product of Magic Pharmaceutical, the sodium cantharidate series anti-tumor injection, is an exclusive domestic variety with a gross profit margin of nearly 90%. The high barrier and high gross profit product attributes are in line with the current preference of funds for scarce varieties in the pharmaceutical sub segment. In addition, influenced by the trend in the pharmaceutical sector, the overall heat of the pharmaceutical sector has remained high since August, with active movements in the fields of chemical pharmaceuticals and anti-tumor drugs. As a small market value pharmaceutical stock, Magic Pharmaceuticals has sufficient short-term elasticity and has become a target of concentrated speculative capital.
Yibai Pharmaceutical is an enterprise that integrates research, development, production, and sales of new drugs. It mainly engages in the research, production, and sales of modern traditional Chinese medicine products, focusing on multiple treatment fields such as cancer, cardiovascular and cerebrovascular diseases, and gynecology. The company's main products are Aidi Injection, Ginkgo Damo Injection (Xingding Injection), Compound Cantharides Capsules (Kangsai Di Capsules), Keke Capsules, etc. As of the end of 2025, the company has 152 varieties and 194 drug production approval numbers, of which 64 varieties have entered the national medical insurance catalog. In terms of chemical anti-tumor drugs, the company has products such as injectable lobaplatin, which is a third-generation platinum compound. It is an exclusive variety, original research drug, and a Class I new drug.
However, the overall performance of Yibai Pharmaceutical's business is poor. Data shows that from 2020 to 2024, the company's operating revenue decreased from 3.413 billion yuan to 2.174 billion yuan, with net profits attributable to the parent company of 220 million yuan, 244 million yuan, -438 million yuan, 103 million yuan, and -317 million yuan, respectively. In 2025, the company achieved a revenue of 1.863 billion yuan, a further year-on-year decrease of 14.31%; The net profit attributable to the parent company was -330 million yuan, with a year-on-year increase in losses. The expected net profit attributable to the parent company for the first half of 2026 is -88.8 million to -74 million yuan.
The analysis points out that the main logic of market speculation on Yibai Pharmaceutical is focused on the game of small market value varieties within the traditional Chinese medicine sector. Yibai Pharmaceutical has a relatively small total market value and is more likely to receive attention from funds when the sector sentiment improves, making it a target for short-term fund rotation mining.